GlassScriptPhysician profile
Sandra Robles-Bonham
NPI 1083867683
$1,593.19
in general payments reported to CMS, 2019-2025
18 companies · $767 in 2025
The $767 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $164 · 2023: $217 · 2024: $445 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,429.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $313.00 | 2024-2025 | Bexsero, Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $283.74 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $215.60 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $166.35 | 2021-2023 | Breztri |
| Merck Sharp & Dohme LLC | $133.26 | 2021-2024 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.44 | 2023-2024 | Xifaxan |
| Corcept Therapeutics | $64.41 | 2025 | Korlym |
| Ardelyx, INC. | $55.77 | 2025 | Ibsrela |
| Redhill Biopharma INC. | $52.66 | 2024-2025 | Talicia |
| Intra-Sana Laboratories | $50.00 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Abbott Laboratories | $47.28 | 2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $37.30 | 2025 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $23.71 | 2023 | Uptravi, Opsumit |
| Astellas Pharma US INC | $21.76 | 2023 | Veozah |
| Abbvie INC. | $18.86 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.44 | 2025 | |
| Idorsia Pharmaceuticals US INC | $14.58 | 2023 | Quviviq |
| Cranial Technologies, INC | $13.03 | 2023 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Robles-Bonham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.